Form 4: Telesis Bio Inc. Director Gregory J. Herrema Acquires Shares and Options

Director Gregory J. Herrema of Telesis Bio Inc. reports acquisition of restricted stock units and stock options.

Summary

• On May 1, 2024, Gregory J. Herrema, a director of Telesis Bio Inc., acquired 31,486 shares of common stock through restricted stock units (RSUs).
• These RSUs represent a contingent right to receive one share of Telesis Bio Inc.'s common stock for each RSU.
• 11,245 of the RSUs will vest on January 1, 2025, contingent upon continued service.
• The remaining 20,241 RSUs will vest on the earlier of the one-year anniversary of the grant date or the date of the annual meeting of the Issuer's stockholders following the date of grant.
• Herrema also acquired 30,362 stock options with an exercise price of $0.3557 on May 1, 2024.
• These options vest on the earlier of the one-year anniversary of the grant date or the date of the annual meeting of the Issuer's stockholders following the date of grant, contingent upon continued service.
• Following these transactions, Herrema directly owns 184,677 shares of common stock and 30,362 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a standard regulatory filing reflecting insider transactions. The acquisition of shares and options could be seen as a positive signal, but it's a routine event.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.
• The vesting schedules of the RSUs and stock options incentivize continued service and alignment with shareholder interests.

Future Outlook

The vesting of RSUs and stock options is contingent upon the Reporting Person continuing as a Service Provider, suggesting an expectation of continued involvement with the company.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when company insiders, like directors, transact in their company's stock. It provides transparency to the market regarding insider activity.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector.
• The vesting schedules described are fairly standard, aligning with typical industry practices for incentivizing long-term commitment.
• Comparable companies such as Codex DNA and Ginkgo Bioworks also utilize stock options and RSUs as part of their compensation packages for directors and executives.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive sign of confidence in the company's future.
• The vesting schedules incentivize the director to remain engaged and contribute to the company's success.

Key Dates

Keywords

Telesis Bio Inc., Gregory J. Herrema, Form 4, insider trading, stock options, restricted stock units, TBIO, director, acquisition